

RTOG Presentations at ASTRO 2006

Brain Tumors

An Update of Phase II Results from RTOG 0211: A Phase I/II Study of Gefitinib with Radiotherapy in Newly-Diagnosed Glioblastoma Multiforme

Chakravarti, A., Berkey, B., Robbins, I., Guha, A., Curran Jr, W., Brachman, D., Schultz, C., Mehta, M.

Validation of EORTC Prognostic Factors for Adults with Low Grade Glioma: A Report Utilizing Intergroup 86-72-51

Brown, P., Daniels, T., Ballman, K., Felton, S., Buckner, J., Arusell, R., Curran Jr, W., Abrams, R., Earle, J. and Shaw, E.

Age as an Independent Prognostic Factor in Patients with Glioblastoma: A Radiation Therapy Oncology Group Analysis

Siker, M., Berkey, B., Nelsen, D., Curran Jr, W., Michalski, J., Souhami, L., Chakravarti, A., Yung, W.A., DelRowe, J., Coughlin, C. and Mehta, M.

Breast Cancer

A Phase II Trial of Brachytherapy Alone Following Lumpectomy for Select Breast Cancer: Tumor Control and Survival Outcomes of RTOG 9517

Arthur, D., Winter, K., Kuske, R.R., Bolton, J.S., Rabinovitch, R., White, J., Hanson, W., Wilenzick, R.M. and McCormack, B.

Cervical Cancer

Celebrex (celecoxib) and Chemoradiation in Patients with Locally Advanced Cervical Cancer. An Efficacy Report of RTOG 0128

Gaffney, D., Winter, K., Dicker, A., Miller, B., Eifel, P., Ryu, J., Avizonis, V.N., Fromm, M. and Greven, K.

Gastrointestinal Cancers

RTOG 9704 - Radiotherapy Quality Assurance (QA) Review and Survival

Abrams, R., Winter, K., Regine, W., Safran, H., Hoffman, J., Konski, A., Benson III, A., MacDonald, J., Rich, T. and Willett, C.

Intergroup RTOG 9811 Phase III Comparison of Chemoradiation with 5-FU and Mitomycin vs 5-FU and Cisplatin for Anal Canal Carcinoma: Impact on Disease-Free, Overall and Colostomy-Free Survival

Gunderson, L., Winter, K., Ajani, J., Pedersen, J., Benson, A., Thomas Jr., C., Mayer, R., Haddock, M., Willet, C. and Rich, T.

Recursive Partitioning Analysis (RPA) of Prognostic Factors in Six Radiation Therapy Oncology Group (RTOG) Trials of Chemoradiotherapy for Unresectable Pancreatic Cancer

Garofalo, M., Winter, K., Regine, W., Rich, T., Komaki, R., Tepper, J., Gunderson, L. and Willett, C.

A Randomized Phase II Study of Two Paclitaxel-Based Chemoradiotherapy Regimens for Patients with Non-operative Esophageal Carcinoma (RTOG 0113)

Komaki, R., Winter, K., Ajani, J., Kelsen, D., Minsky, B., Liao, Z., Bradley, J., Fromm, M., Hornback, D. and Willett, C.

Three-Year Results of RTOG-0012 Randomized Phase II Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer

Mohiuddin, M., Garcia, M., Mitchell, E., Hanna, N., Yuen, A., Nichols, C., Share, R., Hayostek, C. and Willet, C.

Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated with Preoperative Chemoradiation

Reed, V., Krishnan, S., Bhosale, P., Janjan, N., Das, P., Delclos, M., Lowy, A., Mansfield, P., Ajani, J. and Crane, C.

A Phase III Intergroup Trial (RTOG 9704) of Adjuvant Pre- and Post Chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcinoma

Regine, W., Winter, K., Abrams, R., Safran, H., Hoffman, J., Konski, A., Benson III, A., MacDonald, J., Willet, C. and Rich, T.

A Randomized Phase II Trial Comparing Two Paclitaxel (P)-Cisplatin (C) Containing Chemoradiation (CRT) Regimens As Adjuvant Therapy in Resected Gastric Cancer (RTOG 0114)

Schwartz, G., Winter, K., Minsky, B., Janjan, N., Schaefer, P., Thomson, J., Anne, P.R., Gross, H., Willet, C. and Kelsen, D.

Head and Neck Cancer

Long-Term Survival Results of a Phase III Intergroup Trial (RTOG 9501) of Surgery Followed by Radiotherapy vs. Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck

Cooper, J., Pajak, T., Forastiere, A., Jacobs, J., Campbell, B., Saxman, S., Kish, J., Cmelak, A., Kim, H. and Fu, K.

Phase II Multi-Institutional Study of IMRT for Oropharyngeal Cancer (RTOG 0022): Early Results
Eisbruch, A., Harris, J., Chao, C., Garden, A., Straube, W., Schultz, C., Sanguineti, G., Jones, C., Bosch, W. and Ang, K.K.

Results of RTOG 9703 - A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck: Long-term Results and Late Toxicities

Garden, A.S., Harris, J., Vokes, E., Forastiere, A., Ridge, J., Jones, C., Horwitz, E., Glisson, B., Nabell, L. and Cooper, J.

A Randomized Trial of Hyperfractionation versus Standard Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord

Trotti, A., Pajak, T., Emami, B., Hammond, E., Jones, C., Morrison, W., Sagar, S., Ridge, J., Fu, K. and Ang, K.K.

Lung Cancer

Comparison of 5-Year Survival Between RTOG-9410 and a Phase II Study of Induction Chemotherapy Followed by Etoposide + Radiotherapy in Patients with Locally Advanced NSCLC
Choy, H., Swann S., Nabid, A., Stea, B., Roa, W., Souhami, L., Yunus, F., Hackman, J., Beard, S., and Curran Jr, W.:

A Statistical Model of the Risk of Radiation Pneumonitis Based on Combined RTOG and Washington University Data

Deasy, J. O., El Naqa, I., Hope, A. H., Lindsay, P. E., Sause, W. T., Graham, M. L., Bosch, W. R., Matthews, J. W., Bradley, J. D.

Sociodemographic Factors are Significant Predictors of Toxicity in RTOG Non-Operative NSCLC Trials

Movsas, B., Swann, S., Curran Jr, W., Coyne, J., Konski, A., Komaki, R., Bradley, J., Langer, C., Choy, H. and Watkins Bruner, D.

Prostate Cancer

Predictors of Late Toxicities and Symptom Clusters in Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials of High Risk Patients: A Meta-analysis of Physician Rated Toxicities
Watkins-Bruner, D., Moughan, J., Roach III, M., Movsas, B., Konski, A., Hanks, G., Cox, J. and Swann, S.

Pretreatment Tumor Biomarker Stability in Archival Tissue from Men Treated with Radiotherapy for Prostate Cancer: An Analysis of RTOG 9202 and Fox Chase Randomized Trials
Hachem, P., Bae, K., Khor, L.-Y., Hammond, E., Al-Saleem, T., Li, L., Hanks, G., Sandler, H., Pollack, A.

Ten Year Follow-up of RTOG 9202; A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
Hanks, G., Bae, K., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E., Lawton, C., Sandler, H. and Shipley, W.

Cox-2 Overexpression Predicts Prostate Cancer Outcome: An Analysis of RTOG 9202
Khor, L.-Y., Bae, K., Hammond, E., Pollack, A., Venkatesan, V., Rosenthal, S., Sandler, H., Hanks, G., Shipley, W. and Dicker, A.

Biochemical Recurrence and Late Toxicity following External Beam Radiotherapy combined with Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019
Lee, W., Bae, K., Lawton, C., Gillin, M., Morton, G., Firat, S., Baikadi, M., Greven, K., Kuettel, M. and Sandler, H.

Comparison of Two Types of Biochemical Failures within the ASTRO and Phoenix Consensus Definitions in Patients Treated on RTOG 9202 and 9413
Pan, C., Bae, K., Hanks, G., Shipley, W., Roach III, M. and Sandler, H.

Temporal Profile of Serum Testosterone with Goserelin Use and Cessation: Analysis of RTOG Protocol 9202
Pisansky, T.M., Bae, K., Hanks, G.E., Shipley, W.U., Sandler, H.M.

Bcl-2 and Bax Predict Prostate Cancer Outcome In Men Treated With Androgen Deprivation And Radiotherapy on RTOG 9202
Pollack, A., Moughan, J., Khor, L.-Y., Al-Saleem, T., Hammond, E., Venkatesan, V., Rosenthal, S., Hanks, G., Shipley, W. and Sandler, H.

Socio-demographic Predictors of Biochemical Failure and Survival Among High Risk Patients Treated on Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials: A Meta-analysis
Roach III, M., Moughan, J., Movsas, B., Konski, A., Hanks, G., Cox, J. and Watkins-Bruner, D.

Does Testosterone Influence Radiation-induced Toxicity in Radiotherapy of the Prostate? A Secondary Analysis of RTOG Protocol 9413
Taussky, D., Bae, K., Bahary, J.-P., Roach III, M., Lawton, C., Shipley, W. and Sandler, H.

The Prognostic Value of Survivin in Locally Advanced Prostate Cancer: A Study Based on RTOG 8610
Zhang, M., Ho, A., Hammond, E., Sause, W., Pilepich, M., Shipley, W., Sandler, H., Khor, L.-Y., Pollack, A. and Chakravarti, A.

Quality of Life

Pretreatment Quality of Life in a Prospective Lung Cancer Trial: Should Gender Differences be Stratified by Performance Status?

Kohl, R., Swann, S., Bruner, D., Kaiser, L., Sause, W., Choy, H. and Movsas, B.

The Addition of Chemotherapy to Radiation is Cost-Effective in the Treatment of Patients with Locally Advanced Laryngeal Cancer: An Economic Analysis of Radiation Therapy Oncology Group (RTOG) 9111

Konski, A., Bhargavan, M., Owen, J., Paulus, R., Cooper, J., Forastiere, A., Geopfert, H., Ang, K.K. and Bruner, D.

Is There a "Disconnect" Between Physician and Patient-Reported Outcomes (PROs) ? An Analysis of RTOG 9801

Sarna, L., Swann, S., Langer, C., Werner-Wasik, M., Nicolaou, N., Komaki, R., Machtay, M., Smith, C., Axelrod, R. and Movsas, B.

Miscellaneous

A Review of the Activities of the ITC in Support of RTOG Advanced Technology Clinical Trials

Purdy, J., Bosch, W., Straube, W., Matthews, J., Haynes, R., Michalski, J., Martin, E., Winter, K., Curran Jr, W. and Cox, J.

RTOG Participating Physician and Research Associates Attitudes Regarding Clinical Trials: Implications for Improving Recruitment

Walker, E., James, J., Harston, S., Gore, E., Prestidge, B., Michalski, J., Chamberlain, R.M., Gwede, C. and Bruner, D.

Adaptive Protocol Development and Trial Initiation: RTOG's Experience in the Current Clinical Trials Environment

Young, B.K., Martin, E., Hoffman, W., Wudarski, T., King, S., Brasteter, H., Galvin, J. and Curran Jr, W.